ANERGIS The Future of Allergy Treatment: Ultra-Fast Desensitization
Biotechnology - Épalinges, Vaud, Switzerland
ANERGIS The Future of Allergy Treatment: Ultra-Fast Desensitization Employees
ANERGIS The Future of Allergy Treatment: Ultra-Fast Desensitization Details
Anergis is a clinical-stage biopharmaceutical company based in Switzerland. Anergis discovers and develops proprietary synthetic allergy vaccines with the aim to provide allergy patients and doctors with a significantly improved treatment option: ultra-fast immunotherapy. Anergis COP allergy vaccines are pharmaceutical-grade products based on Contiguous Overlapping Peptides (COPs) and only need to be administered for 2 months in order to achieve long-lasting desensitization. Anergis strives to improve the medical treatment of patients suffering from allergies by promoting a shift in treatment paradigms from short-term symptomatic relief to long-term cure from allergies by ultra-fast desensitization. If you are interested to participate in one of our clinical trials, please send an email to info@anergis.ch
ANERGIS The Future of Allergy Treatment: Ultra-Fast Desensitization Technologies
Load Balancers
Nginx
Fonts
Google Font API
Advertising Networks
Google AdSense
Other
Mobile Friendly